Cue Biopharma (CUE) Competitors $0.86 +0.11 (+14.04%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.03 (-3.26%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. CABA, ACRS, VTYX, TNXP, EPRX, SCLX, CRBU, BIOA, BDTX, and MDWDShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Cabaletta Bio (CABA), Aclaris Therapeutics (ACRS), Ventyx Biosciences (VTYX), Tonix Pharmaceuticals (TNXP), Eupraxia Pharmaceuticals (EPRX), Scilex (SCLX), Caribou Biosciences (CRBU), BioAge Labs (BIOA), Black Diamond Therapeutics (BDTX), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Cabaletta Bio Aclaris Therapeutics Ventyx Biosciences Tonix Pharmaceuticals Eupraxia Pharmaceuticals Scilex Caribou Biosciences BioAge Labs Black Diamond Therapeutics MediWound Cabaletta Bio (NASDAQ:CABA) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the media prefer CABA or CUE? In the previous week, Cabaletta Bio had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Cabaletta Bio and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.88 beat Cabaletta Bio's score of 0.63 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is CABA or CUE more profitable? Cabaletta Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -469.35%. Cabaletta Bio's return on equity of -92.11% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -92.11% -74.08% Cue Biopharma -469.35%-230.13%-111.16% Do analysts rate CABA or CUE? Cabaletta Bio currently has a consensus price target of $14.50, indicating a potential upside of 501.66%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Cabaletta Bio is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals believe in CABA or CUE? 35.0% of Cue Biopharma shares are owned by institutional investors. 11.3% of Cabaletta Bio shares are owned by company insiders. Comparatively, 12.3% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, CABA or CUE? Cue Biopharma has higher revenue and earnings than Cabaletta Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.71-0.89Cue Biopharma$9.29M7.10-$40.67M-$0.56-1.53 Which has more volatility & risk, CABA or CUE? Cabaletta Bio has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. SummaryCabaletta Bio beats Cue Biopharma on 10 of the 16 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.94M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-1.5321.8485.6327.59Price / Sales7.10477.40622.26138.47Price / CashN/A47.6737.7861.77Price / Book3.0610.1513.136.76Net Income-$40.67M-$52.31M$3.30B$275.88M7 Day Performance18.57%6.72%5.27%3.71%1 Month Performance10.42%15.01%9.92%10.21%1 Year Performance-30.24%29.35%87.69%35.86% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma2.3976 of 5 stars$0.86+14.0%N/A-45.7%$65.94M$9.29M-1.5360News CoverageShort Interest ↓Gap UpHigh Trading VolumeCABACabaletta Bio2.646 of 5 stars$2.38+0.8%$14.50+509.2%-42.1%$215.86MN/A-0.8850Positive NewsAnalyst ForecastACRSAclaris Therapeutics2.6132 of 5 stars$1.92-3.5%$8.71+353.9%+60.0%$215.58M$18.72M-1.40100Gap UpVTYXVentyx Biosciences1.5453 of 5 stars$3.03+1.7%$7.50+147.5%+87.7%$212.50MN/A-1.8030Analyst ForecastTNXPTonix Pharmaceuticals2.8707 of 5 stars$24.76+2.3%$70.00+182.7%+59.8%$212.22M$9.83M-0.6350Analyst ForecastEPRXEupraxia Pharmaceuticals3.0497 of 5 stars$5.77+0.4%$11.00+90.8%+141.8%$206.41MN/A-6.7829Analyst ForecastAnalyst RevisionHigh Trading VolumeSCLXScilex2.2179 of 5 stars$26.62-8.9%$455.00+1,609.2%-43.1%$203.18M$44.24M-0.9280Analyst ForecastCRBUCaribou Biosciences1.9049 of 5 stars$2.30+8.0%$6.67+189.9%+33.5%$198.35M$9.99M-1.29100Analyst ForecastGap UpBIOABioAge Labs0.2783 of 5 stars$5.45+0.6%N/AN/A$194.31MN/A0.00N/AAnalyst ForecastBDTXBlack Diamond Therapeutics3.5103 of 5 stars$3.73+9.7%$11.00+194.9%+6.8%$193.58MN/A16.2290Positive NewsAnalyst ForecastMDWDMediWound1.6398 of 5 stars$17.97+0.4%$32.25+79.5%+7.5%$193.36M$19.86M-6.8180Analyst Forecast Related Companies and Tools Related Companies Cabaletta Bio Alternatives Aclaris Therapeutics Alternatives Ventyx Biosciences Alternatives Tonix Pharmaceuticals Alternatives Eupraxia Pharmaceuticals Alternatives Scilex Alternatives Caribou Biosciences Alternatives BioAge Labs Alternatives Black Diamond Therapeutics Alternatives MediWound Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
